Clinical Trials
3
Active:0
Completed:2
Trial Phases
1 Phases
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (100.0%)Tolerability, Safety, and Efficacy Study of INGAP Peptide to Treat Type 1 Diabetes Mellitus in Adults
- First Posted Date
- 2009-10-15
- Last Posted Date
- 2014-02-12
- Lead Sponsor
- Exsulin Corporation
- Target Recruit Count
- 23
- Registration Number
- NCT00995540
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇨🇦McGill University - Montreal General Hospital, Montreal, Quebec, Canada
Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- Interventions
- Drug: INGAP-PeptideDrug: placebo
- First Posted Date
- 2003-10-23
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- Exsulin Corporation
- Target Recruit Count
- 126
- Registration Number
- NCT00071422
- Locations
- 🇺🇸
Diabetes and Endocrine Associates, La Jolla, California, United States
🇺🇸VA Hospital UCSD, San Diego, California, United States
🇺🇸Diablo Clinical Research, Walnut Creek, California, United States
Safety and Efficacy of INGAP-Peptide in Patients With Type 1 Diabetes
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Insulin-Dependent
- Interventions
- Drug: placeboDrug: INGAP-Peptide
- First Posted Date
- 2003-10-23
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- Exsulin Corporation
- Target Recruit Count
- 63
- Registration Number
- NCT00071409
- Locations
- 🇺🇸
Radiant Research, Irvine, California, United States
🇺🇸VA Hospital UCSD, San Diego, California, United States
🇺🇸Diablo Clinical Research, Walnut Creek, California, United States
News
No news found